Medtech innovation briefing [MIB296]Published: 10 May 2022
The technology described in this briefing is Granulox … Granulox is a topical sterile haemoglobin spray for managing chronic non-healing wounds … The innovative aspects are that, unlike other oxygen delivery technologies, it is designed to allow oxygen to diffuse through wound exudate … It can also be used in various settings without costly consumables, electrical power or full or partial body coverage in a chamber … The intended place in therapy would be alongside standard care for people with chronic non-healing wounds … The main points from the evidence summarised in this briefing are from 8 studies (1 meta-analysis, 2 randomised controlled trials and 5 observational studies) including a total of 530 people … Seven studies were based in the UK and are generalisable to the NHS … The evidence suggests that Granulox may improve the management of chronic non-healing wounds … Key uncertainties around the evidence are that sample sizes are small, and most studies were not randomised and had a short follow-up period … read more